The epigenetic bottleneck of neurodegenerative and psychiatric diseases
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The orchestrated expression of genes is essential for the development and survival of every organism. In addition to the role of transcription factors, the availability of genes for transcription is controlled by a series of proteins that regulate epigenetic chromatin remodeling. The two most studied epigenetic phenomena are DNA methylation and histone-tail modifications. Although a large body of literature implicates the deregulation of histone acetylation and DNA methylation with the pathogenesis of cancer, recently epigenetic mechanisms have also gained much attention in the neuroscientific community. In fact, a new field of research is rapidly emerging and there is now accumulating evidence that the molecular machinery that regulates histone acetylation and DNA methylation is intimately involved in synaptic plasticity and is essential for learning and memory. Importantly, dysfunction of epigenetic gene expression in the brain might be involved in neurodegenerative and psychiatric diseases. In particular, it was found that inhibition of histone deacetylases attenuates synaptic and neuronal loss in animal models for various neurodegenerative diseases and improves cognitive function. In this article, we will summarize recent data in the novel field of neuroepigenetics and discuss the question why epigenetic strategies are suitable therapeutic approaches for the treatment of brain diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“In AD patients, a shift towards the production of more toxic Ab-peptides, such as Ab42, is commonly observed (Haass and Selkoe, 2007).”
BackgroundGenomic DNA methylation: the mark and its mediators.
Klose, R. J., & Bird, A. P. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.12.008 · Cited by 2,501 · cited 2×
“Such CpG islands also occur in gene promoters and regulate expression of target genes (Klose and Bird, 2006).”
BackgroundModality-Specific Retrograde Amnesia of Fear
Kim, J. J., & Fanselow, M. S. (1992) · Science · doi:10.1126/science.1585183 · Cited by 2,483
Gene regulation and DNA damage in the ageing human brain
Lu, T., Pan, Y., Kao, S.-Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004) · Nature · doi:10.1038/nature02661 · Cited by 1,874
Enriched environments, experience-dependent plasticity and disorders of the nervous system
Nithianantharajah, J., & Hannan, A. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1970 · Cited by 1,771
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644 · cited 1×
“Indeed, a recent study using HDAC2 knockout and HDAC2 overexpressing mice showed that HDAC2 is a negative regulator of memory formation (Guan et al., 2009).”
BackgroundChIP-seq accurately predicts tissue-specific activity of enhancers
Visel, A., Blow, M. J., Li, Z., Zhang, T., Akiyama, J. A., Holt, A., Plajzer-Frick, I., Shoukry, M., Wright, C., Chen, F., et al. (2009) · Nature · doi:10.1038/nature07730 · Cited by 1,639 · cited 1×
“Interestingly, most of those genomic regions were enhancers located far away from the open reading frame of the genes (Visel et al., 2009).”
BackgroundMyers, K. M., & Davis, M. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001939 · Cited by 1,277 · cited 1×
“However, when repeatedly presented with the conditioned context on subsequent days the freezing behavior gradually declines (Myers and Davis, 2007; Fischer and Tsai, 2008).”
BackgroundThe Story of Rett Syndrome: From Clinic to Neurobiology
Chahrour, M., & Zoghbi, H. Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.10.001 · Cited by 1,265 · cited 1×
“Rett syndrome affects 1 in 15 000 individuals and is the secondmost cause for mental retardation in young women (Chahrour and Zoghbi, 2006).”
BackgroundReversal of Neurological Defects in a Mouse Model of Rett Syndrome
Guy, J., Gan, J., Selfridge, J., Cobb, S., & Bird, A. (2007) · Science · doi:10.1126/science.1138389 · Cited by 1,230 · cited 1×
“Although those mutant mice display characteristic symptoms of mental retardation, a recent study demonstrated that HDAC inhibitors could reverse some of the symptoms (Guy et al., 2007).”
Cited by
Histone acetylation: molecular mnemonics on the chromatin
Gräff, J., & Tsai, L.-H. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3427 · Cited by 680
DNA methylation and memory formation
Day, J. J., & Sweatt, J. D. (2010) · Nature Neuroscience · doi:10.1038/nn.2666 · Cited by 486
Targeting the correct HDAC(s) to treat cognitive disorders
Fischer, A., Sananbenesi, F., Mungenast, A., & Tsai, L.-H. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.003 · Cited by 354
Self-citationReducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease
Govindarajan, N., Rao, P., Burkhardt, S., Sananbenesi, F., Schlüter, O. M., Bradke, F., Lu, J., & Fischer, A. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201923 · Cited by 342
Self-citationMolecular Coupling of DNA Methylation and Histone Methylation
Hashimoto, H., Vertino, P. M., & Cheng, X. (2010) · Epigenomics · doi:10.2217/epi.10.44 · Cited by 286
Epigenetic Regulation of Learning and Memory by Drosophila EHMT/G9a
Kramer, J. M., Kochinke, K., Oortveld, M. A. W., Marks, H., Kramer, D., de Jong, E. K., Asztalos, Z., Westwood, J. T., Stunnenberg, H. G., Sokolowski, M. B., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1000569 · Cited by 204
“disorders, such as schizophrenia and intellectual disability (previously referred to as mental retardation) [4,5].”
BackgroundEpigenetics in Alzheimer’s Disease: Perspective of DNA Methylation
Qazi, T. J., Quan, Z., Mir, A., & Qing, H. (2018) · Molecular Neurobiology · doi:10.1007/s12035-016-0357-6 · Cited by 153
Emerging risk of environmental factors: insight mechanisms of Alzheimer’s diseases.
Rahman, M. A., Rahman, M. S., Uddin, M. J., Mamum-Or-Rashid, A. N. M., Pang, M.-G., & Rhim, H. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-08243-z · Cited by 115
Epigenetic memory: The Lamarckian brain
Fischer, A. (2014) · The EMBO Journal · doi:10.1002/embj.201387637 · Cited by 107
“More common is however the late onset form (loAD) of AD that comprises 95% of all cases and is driven by variable combinations of genetic and environmental risk factors (Sananbenesi & Fischer, 2009; Goate & Hardy, 2012).”
Self-citationRusiecki, J. A., Byrne, C., Galdzicki, Z., Srikantan, V., Chen, L., Poulin, M., Yan, L., & Baccarelli, A. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00056 · Cited by 99
Harkess, K. N., Ryan, J., Delfabbro, P. H., & Cohen-Woods, S. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.234 · Cited by 80
Parvalbumin Promoter Hypermethylation in Postmortem Brain in Schizophrenia
Fachim, H. A., Srisawat, U., Dalton, C. F., & Reynolds, G. P. (2018) · Epigenomics · doi:10.2217/epi-2017-0159 · Cited by 41
“6 responses [27], so epigenetic dysfunction in these elements in the brain might be 172 involved in neurodegenerative and psychiatric diseases [28].”
Metadata
- Authors
- Sananbenesi, F., & Fischer, A.
- Venue
- bchm
- Publisher
- Walter de Gruyter GmbH
- Published
- 2009-09-13
- Volume
- 390
- Issue
- 11
- Pages
- 1145-1153
- ISSN
- 1431-6730 (ISSN-L)
- 1437-4315
- OpenAlex
- W2088308633
- Cited by
- 106
- References
- 26
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.